Fat Necrosis After Fat Transfer: The Lump That Is Not Supposed to Be There

Six months after a fat transfer to the breast, a patient finds a firm, pea-sized lump near the edge of where the volume went. It does not hurt. It does not move much. Her primary care physician orders imaging, the radiologist flags an irregular density with calcification, and she spends a week believing she has cancer before a biopsy comes back as what the surgeon could have told her on day one: fat necrosis.

That sequence plays out often enough to deserve its own explanation. This is the fifth entry in a series on how cosmetic operations go wrong, after the seroma, the facelift hematoma, the incision that opens, and the drain built to prevent all three. Fat necrosis is different from those in one important way. It is not a failure of technique layered on top of a successful operation. It is the ordinary biology of fat grafting, showing up in a form the patient can feel.

What fat necrosis actually is

The short answer: fat necrosis is what happens when transplanted fat cells die before they can acquire a blood supply, and the body walls off the debris instead of clearing it.

A fat graft is not a transplant in the way a kidney is. Nothing is sewn to a blood vessel. The surgeon harvests fat by liposuction, processes it, and injects it in thin strands into the recipient site, where each adipocyte has to survive by diffusion until new capillaries grow into it. That takes days. As covered in the piece on graft survival biology, a cell more than roughly two millimeters from a blood supply is unlikely to make it, which is why retention across the published literature ranges from about 30 to 80 percent depending on site, technique, and patient.

The fat that does not survive has to go somewhere. In the best case, macrophages digest the dead cells and the volume quietly resorbs over three to six months, which is the ordinary "settling" every fat transfer patient is warned about. In the worse case, a cluster of dead adipocytes is too large to clear. Released triglycerides pool into an oil cyst, the surrounding tissue forms a fibrous capsule around it, and over months the capsule wall can calcify. That is the palpable lump: a scarred, sometimes calcified pocket of liquefied fat.

The pathology is benign, always. Fat necrosis is not precancerous and does not become cancer. The problem is that it can look and feel like cancer, and in the breast, that resemblance has consequences.

"

Fat necrosis is not a complication layered on top of a fat graft. It is the part of every fat graft that died, made visible.

"

How often it happens, and where

The short answer: in the breast, clinically detectable fat necrosis after grafting runs somewhere between 2 and 15 percent in most published series, and the rate climbs with the volume injected per session.

The breast is where the literature is deepest because the stakes are highest. Systematic reviews in Plastic and Reconstructive Surgery and Aesthetic Surgery Journal covering thousands of cosmetic and reconstructive fat-grafting patients put palpable fat necrosis in the single digits for modest-volume augmentation and into the teens for large-volume or repeated grafting. Radiographic fat necrosis, meaning findings on imaging the patient cannot feel, is more common than that. One of the more consistent findings across studies is that the rate tracks with how much fat was placed in one sitting. A surgeon who puts 400 milliliters into a breast that comfortably accepts 200 is not getting a bigger result. The excess dies in the center of the bolus where no capillary can reach, and that dead core is the future lump.

In the face, necrosis is less common and less consequential, partly because volumes are small and partly because the tissue is well vascularized. Where it does occur, it tends to present as a firm nodule in the cheek, the tear trough, or the lip, or as a visible contour irregularity. Facial fat grafting carries its own, rarer, and far more serious vascular risk (injection into an artery), which is a separate subject from necrosis of the graft itself.

In the buttock, the calculus changes again. The Brazilian butt lift moves the largest volumes of any grafting procedure, and the safety protocols that have reshaped that operation were written to prevent fat embolism, not necrosis. But necrosis is common at BBL volumes, and firm areas, oil cysts, and occasionally infected collections that need drainage are a recognized part of the recovery landscape that many consultations skip.

A few patterns hold across all three sites:

• Larger single boluses produce more necrosis than the same volume spread in thin, separated strands across multiple planes.
• Poorly vascularized recipient tissue (scarred, radiated, or very tight) retains less graft and produces more necrosis.
• Smokers and patients with poor glycemic control graft worse, for the same perfusion reasons that affect every other wound in plastic surgery.
• Repeat sessions into the same area raise the cumulative odds of a palpable finding.

How it is told apart from a tumor

The short answer: imaging usually settles it, a biopsy settles it when imaging does not, and the single most useful piece of information a radiologist can have is that fat was grafted there.

On a mammogram, early fat necrosis can appear as an oil cyst with a thin, smooth wall, which radiologists recognize readily and classify as benign. Later, as the capsule calcifies, it can produce coarse, rim-like "eggshell" calcifications that are also characteristic. The trouble comes in the middle phase and in atypical cases, where the lesion is an irregular spiculated density or a cluster of fine calcifications that can mimic carcinoma. Ultrasound adds information (a complex cyst with a fatty component is reassuring), and MRI is the tiebreaker, because fat-suppressed sequences can show the lesion follows fat signal.

The American College of Radiology and the American Society of Plastic Surgeons both now treat fat grafting as compatible with breast cancer screening, a shift from the position of a decade ago. As the imaging after cosmetic breast surgery piece laid out, the evidence is that grafted breasts have a modestly higher rate of additional imaging and benign biopsies, not a higher rate of missed cancers. That is the honest trade: more callbacks, not more danger, provided the radiologist is reading with the right history.

Which is the practical point. A patient who does not tell the imaging center she had fat grafting is setting up the exact scenario that opened this piece. The radiologist sees calcifications in a breast with no surgical history and has no benign explanation to reach for. The one who knows about the graft, and ideally has a baseline study from six to twelve months after surgery, can compare, watch a stable lesion, and spare the patient a needle.

When imaging cannot resolve it, a core needle biopsy does. The pathology of fat necrosis (foamy macrophages, lipid-laden cysts, fibrosis) is distinctive and the finding is definitive. Patients sometimes resist the biopsy as overkill for a cosmetic side effect. It is not. In a breast that was grafted, a new mass has a benign explanation available, and that is precisely why it needs to be proven rather than assumed.

What surgeons can and cannot control

The short answer: technique controls the size of the dead zones, patient factors control the perfusion, and nobody controls the retention rate precisely enough to promise a result.

The Coleman technique and its descendants exist almost entirely to minimize necrosis. Low-pressure harvest to keep the cells intact, gentle processing (centrifugation, washing, or filtration, each with advocates and without a clear winner in the literature), and placement of small aliquots, fractions of a milliliter per pass, through many tunnels in many planes. The logic is geometric: a thin cylinder of fat has a high surface-to-volume ratio and every cell is near host tissue. A pool of fat has a core that starves.

Beyond that, the evidence gets softer. Pre-expansion of the breast with external negative pressure devices before grafting was shown to improve retention in some series and has not been widely adopted, in part because patient compliance with weeks of wearing a suction dome is poor. Enriching the graft with stromal vascular fraction or platelet-rich plasma has generated a large and inconsistent literature, and the FDA position on stem cell claims is that most of what is marketed under that banner is not approved for the purpose. A surgeon who presents any enrichment as the solution to necrosis is ahead of the data.

On the patient side, the levers are familiar from every other piece in this series: no nicotine in any form for several weeks on either side of surgery, glucose under control, weight stable, and compression used as directed rather than cranked tight over the graft, which can compromise the perfusion the cells are waiting for. What patients cannot do is will a higher retention rate. The surgeon who tells you "expect 60 to 70 percent to stay, and we will know at six months" is being accurate. The one who says "what you see on the table is what you keep" is not.

When a lump needs treatment

The short answer: most fat necrosis needs nothing but a diagnosis, and the small fraction that needs treatment is the fraction that hurts, grows, becomes infected, or distorts the result.

A firm, stable, painless nodule that has been characterized on imaging can be left alone indefinitely. Many soften over a year or two as the oil cyst is slowly resorbed. Some never change, and a calcified nodule in a breast is a permanent radiographic finding that future mammograms will simply note. That is an acceptable outcome and should be framed as one.

Intervention is reasonable when the lesion is large enough to be visible or to distort the contour, when it is tender, when it enlarges rather than stabilizes, or when it becomes an infected collection with redness, warmth, and fever, which is more common after large-volume buttock grafting than anywhere else. Options run from needle aspiration of a liquid oil cyst (quick, sometimes curative, sometimes followed by recurrence), to ultrasound-guided drainage of an infected collection with antibiotics, to surgical excision of a solid calcified mass. Excision leaves a scar and a volume deficit, which is the irony of treating a fat transfer complication: you may end up removing the fat you paid to have placed. Injecting steroid into a fibrous nodule is sometimes tried and has a thin evidence base.

Revision grafting into an area of previous necrosis is possible once the tissue has settled, usually at a year, but the recipient bed is scarred and retention will be lower the second time. That is worth knowing before the first session, because it is one more argument for the surgeon who stages conservatively over the one who promises everything in a single operation.

The honest summary

Fat necrosis is not a rare complication of fat transfer. It is the ordinary fate of the portion of every graft that does not survive, and in a minority of patients (higher with large volumes, in scarred tissue, and in smokers) it becomes a lump that can be felt. The lump is always benign. In the face and buttock it is mostly a contour problem. In the breast it is a diagnostic problem, because it can mimic cancer on imaging, and the fix for that is not avoiding the procedure but documenting it: tell every imaging center, get a baseline study, and accept that a grafted breast generates more callbacks.

The surgeon's side of the bargain is volume discipline and placement technique, and those are things you can ask about. A practice that sets a per-session ceiling, explains it in terms of what the tissue can feed, stages a larger result across two operations, and has a written pathway for the six-month lump is managing the biology. A practice that quotes the volume you want, promises that what you see is what you keep, and has no answer for "what if I feel something" is selling a result it cannot deliver and leaving you to discover the difference alone in a radiology waiting room.